These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10409876)

  • 1. [New cytostatic drugs--indications and costs].
    Schefer H; Lehmann B; Joss R
    Praxis (Bern 1994); 1999 Apr; 88(18):791-801. PubMed ID: 10409876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs of conducting clinical research.
    Emanuel EJ; Schnipper LE; Kamin DY; Levinson J; Lichter AS
    J Clin Oncol; 2003 Nov; 21(22):4145-50. PubMed ID: 14559889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents.
    Argiris A; Murren JR
    Cancer J; 2001; 7(3):228-35. PubMed ID: 11419031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line chemotherapy for non-small cell lung cancer.
    Shepherd FA
    Expert Rev Anticancer Ther; 2003 Aug; 3(4):435-42. PubMed ID: 12934656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neytumorin as biomodular onco-therapy--allegations without documentation].
    Allewelt MC; Hauser SP
    Praxis (Bern 1994); 1997 Apr; 86(18):750-61. PubMed ID: 9244964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.
    Awada A
    Forum (Genova); 2002; 12(1):4-15. PubMed ID: 12634907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Routine chemotherapeutic drug treatment effectiveness predictive molecules and chemotherapeutic drug selection].
    Zhao XD; Zhang Y
    Ai Zheng; 2006 Dec; 25(12):1577-80. PubMed ID: 17166391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
    Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
    Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [[How to finance chemotherapy with new cancer drugs?].
    Livartowski A; Beuzeboc P; Le Vu B; Courbard M; Pierga JY; Extra JM; Scholl S; Pouillart P
    Bull Cancer; 2000 Oct; 87(10):745-54. PubMed ID: 11084538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 13. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 16. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
    Markman M
    Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs for the treatment of cancer, 1990-2001.
    Geffen DB; Man S
    Isr Med Assoc J; 2002 Dec; 4(12):1124-31. PubMed ID: 12516906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytostatic therapy in cancer--a SBU report].
    Glimelius B; Nygren P; Lamnevik G
    Lakartidningen; 2001 Apr; 98(16):1905-10. PubMed ID: 11370407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.